Related Experiment Video
Updated: Apr 18, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
14.5K
CD44-SLC1A2 fusion transcripts in primary colorectal cancer
Kazuya Shinmura1, Hisami Kato, Hisaki Igarashi
1Department of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192, Japan, kzshinmu@hama-med.ac.jp.
Pathology Oncology Research : POR
|January 11, 2015
Summary
A CD44-SLC1A2 fusion transcript was found in one primary colorectal cancer (CRC) but not in lung cancers. This SLC1A2 fusion may characterize a subset of CRCs and influence their properties.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Solute carrier family 1 member 2 (SLC1A2) fusions have been identified in gastric cancer and a colon cancer cell line.
- The occurrence and specificity of SLC1A2 fusions in primary colorectal cancer (CRC) and other cancers remain largely unknown.
Purpose of the Study:
- To investigate the presence of CD44-SLC1A2 and APIP-SLC1A2 fusion transcripts in primary colorectal cancers (CRCs) and non-small cell lung cancers (NSCLCs).
- To characterize the clinicopathological features of CRC harboring SLC1A2 fusions.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) and sequencing were used to detect fusion transcripts.
- Quantitative RT-PCR was employed to analyze SLC1A2 mRNA expression levels.
- Immunohistochemistry and mutation analyses were performed on fusion-positive CRC.
Main Results:
- CD44-SLC1A2 fusion transcripts were detected in one (1.1%) primary CRC but not in any NSCLCs.
- The fusion involved CD44 exon 1 and SLC1A2 exon 2, potentially producing a functional, truncated SLC1A2 protein.
- SLC1A2 mRNA was upregulated in the fusion-positive CRC compared to other CRCs where it was downregulated.
- The fusion-positive CRC was right-sided, mucinous adenocarcinoma, MSH2-negative, and lacked APC/KRAS mutations.
Conclusions:
- SLC1A2 fusion transcripts, specifically CD44-SLC1A2, are present in a subset of primary CRCs.
- These findings suggest SLC1A2 fusions are not exclusive to gastrointestinal cancers but may be specific to certain subtypes.
- Further research into SLC1A2 fusion-positive CRCs is warranted to understand their unique characteristics and clinical implications.
